Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days
Cephalalgia · 2025
DOI: 10.1177/03331024251332519 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cephalalgia, 2025. Verfasst von Rut Mas-de-Les-Valls und 6 weiteren Autor:innen. Beteiligte Einrichtung: Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Barcelona, Spain. Hauptthemen laut MEDLINE: Migraine Disorders, Calcitonin Gene-Related Peptide, Botulinum Toxins, Type A, Antibodies, Monoclonal. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Data on the effectiveness of preventive treatments on menstrually-related migraine (MRM) is scarce. Our objective was to analyze the efficacy of anti-calcitonin gene-related peptide monoclonal antibodies (anti-CGRP mAbs) and onabotulinumtoxinA (BTX-A) in the reduction of perimenstrual headache days (PHD) and perimenstrual migraine days (PMD) compared to non-perimenstrual headache days (non-PHD) and non-perimenstrual migraine days (non-PMD) per month in women with MRM.
Methods
A retrospective study was conducted including females with menstruation and headache records, treated with either anti-CGRP mAbs or BTX-A. Patients completed e-Diary one month before and three months after preventive treatment. We collected clinical data and analyzed PHD/PMD and non-PHD/non-PMD before and after treatment. Additional analyses included PHD/PMD and non-PHD/non-PMD comparisons grouped by aura, episodic/chronic migraine, treatment and contraceptive intake.
Results
We analyzed data from 113 females with a median (range) age of 39.0 (33.0–45.0) years. When combining patients treated with anti-CGRP mAbs or BTX-A, a median (range) of 2.0 (2.0–3.0) PHD/month (corresponding to 13.6% baseline monthly headache days (MHD)) and 13.0 (9.0–17.0) non-PHD/month pre-treatment was observed. From these, 2.0 (1.0–3.0) were PMD/month, and 7.0 (4.0–11.0) were non-PMD/month. After treatment, the median PHD/month was 2.0 (1.0–3.0) (corresponding to 16.67% of MHD) ( p = 0.085), and 8.0 (5.0–13.0) were non-PHD/month ( p < 0.001); from these, 1.0 (0.0–3.0) were PMD/month (proportion difference, p = 0.035) and 4.0 (2.0–7.0) were non-PMD (proportion difference, p < 0.001). When analyzing grouped by treatment, only patients treated with anti-CGRP experienced a reduction in PMD. No statistically significant differences in clinical factors (aura, migraine diagnosis, contraceptive intake) between PHD/non-PHD or PMD/non-PMD, either pre- or post-treatment. A higher probability risk of headache and migraine during the perimenstrual window was observed independently of the treatment received (odds ratio = 1.637, 95% confidence interval = 1.356–1.984, p < 0.001).
Conclusions
Three-month treatment with anti-CGRP mAbs or BTX-A effectively reduced non-PHD and non-PMD but had limited effect on PHD/PMD because headache probability risk was higher during the perimenstrual window after treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Barcelona, Spain.
- Headache Clinic, Neurology Department, Hospital Universitari Vall d'Hebron, Department of Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain.
ORCID-Profile: Rut Mas-de-Les-Valls, Laura Gómez-Dabó, Edoardo Caronna, Victor J Gallardo, Alicia Alpuente, Marta Torres-Ferrus, Patricia Pozo-Rosich
Zitieren
APA
Mas-de-Les-Valls, R., Gómez-Dabó, L., Caronna, E., Gallardo, V. J., Alpuente, A., Torres-Ferrus, M., & Pozo-Rosich, P. (2025). Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days. Cephalalgia. https://doi.org/10.1177/03331024251332519
Vancouver
Mas-de-Les-Valls R, Gómez-Dabó L, Caronna E, Gallardo VJ, Alpuente A, Torres-Ferrus M, et al. Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days. Cephalalgia. 2025. doi:10.1177/03331024251332519
BibTeX
@article{MasdeLesValls2025,
author = {Mas-de-Les-Valls, Rut and Gómez-Dabó, Laura and Caronna, Edoardo and Gallardo, Victor J and Alpuente, Alicia and Torres-Ferrus, Marta and Pozo-Rosich, Patricia},
title = {Effectiveness of anti-CGRP monoclonal antibodies and onabotulinumtoxinA in menstrually-related migraine: The unmet need of perimenstrual headache days},
journal = {Cephalalgia},
year = {2025},
doi = {10.1177/03331024251332519}
}
EUVIMED